METTL17 and neoplasm: Indeed, METTL17 knockdown sensitized SW620 xenograft tumors to ML162 treatment, showcasing a synergistic effect for CRC therapy, as evidenced by the decrease in tumor volume, size and weight (Fig. 7A and B).